{"groups":[{"description":"Participants were administered lazertinib 240 milligrams (mg) tablet orally once daily from Cycle 1 Day 1 until Cycle 15, with each cycle consisting of 28 days. Participants then received amivantamab subcutaneous injection with at dose 1600 mg (if body weight \\[BW\\] is less than \\[\\<\\] 80 kilograms \\[kg\\]) or 2240 mg (if BW is greater than or equal to \\[\\>=\\] 80 kg) co-formulated (SC-CF) with recombinant human hyaluronidase PH20 (rHuPH20) 160 milligrams per milliliter (mg/mL) through manual injection on Cycle 1 Days 1, 8, 15, and 22, and on Days 1 and 15 of each subsequent cycle, starting from Cycle 2. After the completion of primary analysis, participants who benefited from the study treatment continued their treatment within the study upon transitioning into the LTE phase.","id":"FG000","title":"Arm A: Lazertinib With Amivantamab SC-CF"},{"description":"Participants were administered lazertinib 240 mg orally once daily from Cycle 1 Day 1 until Cycle 15, with each cycle consisting of 28 days. Participants then received amivantamab intravenous infusion at dose 1050 mg (if BW\\< 80 kg) or 1400 mg (if BW \\>=80 kg) on Cycle 1 Days 1-2 (split dose), 8, 15, 22, and on Days 1 and 15 of each subsequent cycle, starting from Cycle 2. After the completion of primary analysis, participants who benefited from the study treatment continued their treatment within the study upon transitioning into the LTE phase.","id":"FG001","title":"Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"8"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"156"},{"groupId":"FG001","numSubjects":"141"}],"type":"Other-Ongoing"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"206"},{"groupId":"FG001","numSubjects":"212"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"206"},{"groupId":"FG001","numSubjects":"210"}],"type":"Treated (Safety Analysis)"},{"achievements":[{"groupId":"FG000","numSubjects":"43"},{"groupId":"FG001","numSubjects":"62"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"163"},{"groupId":"FG001","numSubjects":"150"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"The results are currently reported for primary analysis till clinical cut-off date 03-Jan-2024. Upon completion of the open-label follow-up phase, participants were permitted to enter the long-term extension (LTE) phase. The LTE phase is ongoing and results will be published after the completion of the study."}